Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 19 - Any |
| Updated: | 1/16/2019 |
| Start Date: | October 11, 2018 |
| End Date: | December 11, 2020 |
| Contact: | Raven Smith |
| Email: | raven.smith@ucsf.edu |
| Phone: | 415-353-9448 |
The investigators are imaging patients with prostate cancer using a new PET imaging agent
(Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.
(Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.
Inclusion Criteria:
1. Histopathologically proven prostate adenocarcinoma.
2. Concern for metastatic disease in the following settings:
1. Initial staging with intermediate to high risk prostate cancer.
2. Biochemical recurrence after initial therapy.
3. Karnofsky performance status of ≥50 (or ECOG/WHO equivalent).
4. Age > 18.
5. Ability to understand a written informed consent document, and the willingness to sign
it.
Exclusion Criteria:
1. Unable to lie flat, still or tolerate a PET scan.
We found this trial at
1
site
San Francisco, California 94107
Principal Investigator: Thomas Hope, MD
Phone: 415-353-9448
Click here to add this to my saved trials
